Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | SVP-HR and Org. Development | March 10, 2022 | March 14, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date March 10, 2022 · Filed March 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2032-03-10 | Direct | 70,000 |
Reported balance
After 2022-03-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-10 · Grant · Acquired 70,000 · Balance 70,000 F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2022 Filed Mar 14, 2022 15:26 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001214659-22-003900 · marketforms-55767.xml · derivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-03-10 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 21:10 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001214659-21-003155 · marketforms-51883.xml · derivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001214659-20-002753 · marketforms-48340.xml · derivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-03-16 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 1,000 | $3.99 | $3,990.00 |
DisclosureSEC source: 0001214659-19-005184 · marketforms-45480.xml · nonDerivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,765 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:44 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001214659-19-001748 · marketforms-44367.xml · derivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries. Read SEC document |
| November 26, 2018 Filed Nov 26, 2018 19:53 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | PurchaseCommon Stock | 500 | $10.34 | $5,170.00 |
DisclosureSEC source: 0001140361-18-043665 · form4.xml · nonDerivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,765 Read SEC document |
| July 24, 2018 Filed Jul 27, 2018 01:16 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (Right to Purchase) · Derivative | 1,958 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-18-033748 · form4.xml · derivative · entry 1 Wood Theresa · CIK 0001739784 · SVP-HR and Org. Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2028-07-24 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Ms. Wood's continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.